Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)
- PMID:21505316
- PMCID: PMC3103767
- DOI: 10.1097/QAD.0b013e328346bd3e
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)
Abstract
Objectives: The study was designed to assess the safety, adherence, acceptability, and effect on vaginal microflora of 3% SPL7013 Gel (VivaGel), a novel dendrimer topical microbicide that inhibits HIV, herpes simplex virus-2, and human papillomavirus in vitro and in animal models.
Design: Phase 1, randomized, double-blind, placebo-controlled study on sexually active women.
Methods: Sixty-one sexually active women aged 18-24 years were recruited from three sites in the United States. Participants were randomized 1: 1: 1 to receive VivaGel, VivaGel placebo, or a hydroxyethylcellulose (HEC) placebo twice daily for 14 consecutive days. Safety endpoints included genitourinary and/or other adverse events. Changes in vaginal flora were determined from Gram-stained vaginal smears and quantitative vaginal culture.
Results: No serious adverse events or withdrawals due to adverse events were reported. Genitourinary symptoms were reported as follows: VivaGel (n = 17/22; 77.3%), VivaGel placebo (n = 14/21; 66.7%), and HEC (n = eight of 18; 44.4%; not significant, P = 0.1). The incidence of abnormal pelvic examination findings was similar across all gel arms of the study. Using pairwise comparison, women in the VivaGel arm had a significantly higher incidence of related genitourinary adverse events compared with women in the HEC gel arm (0.297 versus 0.111 per 100 person-years, respectively; P = 0.003). Exposure to VivaGel and VivaGel placebo resulted in minor shifts in the vaginal microflora, but there was no overall impact on incidence of bacterial vaginosis as assessed by Nugent score.
Conclusion: VivaGel was generally well tolerated and comparable with the VivaGel placebo, although there was a higher incidence of low-grade related genital adverse events compared to the HEC placebo gel.
Trial registration: ClinicalTrials.govNCT00442910.
Figures
Similar articles
- Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.O'Loughlin J, et al.Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.Sex Transm Dis. 2010.PMID:19823111Clinical Trial.
- Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.Chavoustie SE, Carter BA, Waldbaum AS, Donders GGG, Peters KH, Schwebke JR, Paull JRA, Price CF, Castellarnau A, McCloud P, Kinghorn GR.Chavoustie SE, et al.Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:13-18. doi: 10.1016/j.ejogrb.2019.11.032. Epub 2019 Nov 28.Eur J Obstet Gynecol Reprod Biol. 2020.PMID:31812702Clinical Trial.
- A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, Shiboski S.Cohen CR, et al.PLoS One. 2011 Jan 20;6(1):e16258. doi: 10.1371/journal.pone.0016258.PLoS One. 2011.PMID:21311578Free PMC article.Clinical Trial.
- VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.Rupp R, Rosenthal SL, Stanberry LR.Rupp R, et al.Int J Nanomedicine. 2007;2(4):561-6.Int J Nanomedicine. 2007.PMID:18203424Free PMC article.Review.
- Current and future microbicide approaches aimed at preventing HIV infection in women.Pozzetto B, Delézay O, Brunon-Gagneux A, Hamzeh-Cognasse H, Lucht F, Bourlet T.Pozzetto B, et al.Expert Rev Anti Infect Ther. 2012 Feb;10(2):167-83. doi: 10.1586/eri.11.173.Expert Rev Anti Infect Ther. 2012.PMID:22339191Review.
Cited by
- The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Ferguson LM, Rohan LC.Ferguson LM, et al.Ther Deliv. 2011 Dec;2(12):1535-50. doi: 10.4155/tde.11.126.Ther Deliv. 2011.PMID:22468220Free PMC article.Review.
- Non-Antiretroviral Microbicides for HIV Prevention.Scott Y, Dezzutti CS.Scott Y, et al.AIDS Rev. 2016 Jul-Sep;18(3):145-150.AIDS Rev. 2016.PMID:27438574Free PMC article.
- The role of nanotechnology in the treatment of viral infections.Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R.Singh L, et al.Ther Adv Infect Dis. 2017 Jul;4(4):105-131. doi: 10.1177/2049936117713593. Epub 2017 Jul 5.Ther Adv Infect Dis. 2017.PMID:28748089Free PMC article.Review.
- Promising Drug Delivery Approaches to Treat Microbial Infections in the Vagina: A Recent Update.Pandey M, Choudhury H, Abdul-Aziz A, Bhattamisra SK, Gorain B, Carine T, Wee Toong T, Yi NJ, Win Yi L.Pandey M, et al.Polymers (Basel). 2020 Dec 23;13(1):26. doi: 10.3390/polym13010026.Polymers (Basel). 2020.PMID:33374756Free PMC article.Review.
- Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases.França RF, da Silva CC, De Paula SO.França RF, et al.Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):723-8. doi: 10.1007/s10096-013-1813-0. Epub 2013 Jan 22.Eur J Clin Microbiol Infect Dis. 2013.PMID:23339016Free PMC article.Review.
References
- Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, et al. Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19(14):1525–1534. - PubMed
- McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis. 2010;23(1):26–31. - PubMed
- McCarthy TD, Karellas P, Henderson SA, Giannis M, O’Keefe DF, Heery G, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005;2(4):312–318. - PubMed
Publication types
MeSH terms
Substances
Associated data
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical